Cargando…
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Programmed cell death protein-1 (PD-1)-mediated immunosuppression has been proposed to contribute to the limited clinical efficacy of chimeric antigen receptor T (CAR-T) cells in solid tumors. We generated PD-1 and T cell receptor (TCR) deficient mesothelin-specific CAR-T (MPTK-CAR-T) cells using CR...
Autores principales: | Wang, Zhenguang, Li, Na, Feng, Kaichao, Chen, Meixia, Zhang, Yan, Liu, Yang, Yang, Qingming, Nie, Jing, Tang, Na, Zhang, Xingying, Cheng, Chen, Shen, Lianjun, He, Jiaping, Ye, Xun, Cao, Wei, Wang, Haoyi, Han, Weidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429583/ https://www.ncbi.nlm.nih.gov/pubmed/34381179 http://dx.doi.org/10.1038/s41423-021-00749-x |
Ejemplares similares
-
Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023) -
Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019) -
Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022) -
The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice
por: Zhang, Qian, et al.
Publicado: (2021) -
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)